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Introduction
Inhibitors of tumor necrosis factor (iTNF) are drugs used
to control chronic inflammatory arthritis in cases that are
refractory to treatment with DMARDS. TNF is critical in
preventing Mycobacterium tuberculosis reactivation;
thereby decreased TNF-a activity suggests that the cyto-
kine has a key role in the control of latent tuberculosis.
Objectives
To describe the presentation of Tuberculosis (TB) in
3 patients using iTNF treated at the Rheumatology
Department of the Hospital Universitário Clementino
Fraga Filho, Universidade Federal do Rio de Janeiro
(HUCFF-UFRJ).
Methods: Case Report
Case 1: Female patient, 20 yo, with back pain for two
years, right sacroiliitis confirmed by scintigraphy and
biopsy. She was treated with indomethacin, prednisone,
sulfasalazine and metotretaxe showing no significant
improvement for one year. Etanercept was initiated
with prior normal chest Rx and negative PPD. After
7 months of use, the patient presented fever associated
to pleural effusion in the right hemithorax. The biopsy
was consistent with pleural tuberculosis. She was
treated with rifampicin, isoniazid, pyrazinamide and
streptomycin with complete recovery of pulmonary
infection.
Case 2: Female patient, 5 years old with juvenile idio-
pathic arthritis (JIA) polyarticular RF negative. Initially
treated with naproxen, methotrexate, prednisone, and
folic acid without clinical improvement. After 6 months
of treatment, it was initiated infliximab, with prior
normal chest Rx and negative PPD with control of the
joint symptoms. After 7 months of use, the patient
developed severe pneumonic miliary tuberculosis. She
was treated with rifampicin, isoniazid, pyrazinamide.
The patient resolved her pulmonary infection and
remains in remission of JIA, after 7 years of follow-up.
Case 3: Male patient, 17 years old, ankylosing spondylitis
for 3 years, treated with methotrexate, naproxen, sulfasala-
zine and prednisone with poor response. He was started
on infliximab for 6 years until he presented productive
cough with headache and fever, CXR was consistent with
pulmonary tuberculosis. He was treated with rifampicin,
isoniazid, pyrazinamide for 6 months. The iTNF was chan-
ged for adalimumab with control of the disease.
Results
Several authors describe that the risk of reactivation of
TB increases five to ten times, appearing in a range of
up to 1 year after starting iTNF therapy. In case 3, the
prolonged time between iTNF administration and the
infection suggests that new tuberculosis infection (rein-
fection) occurred. All patients had normal chest RX and
PPD negative at the beginning of the treatment.
Conclusion
Despite having revolutionized rheumatologic practice,
the use of iTNF in the treatment of autoimmune dis-
eases increases the risk of tuberculosis infection and
should be carefully monitored especially in countries
with high prevalence of TB.
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